Biblio
Found 23 results
Author Keyword Title Type [ Year
Filters: Author is Nicoletta Colombo [Clear All Filters]
“BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.”, Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.
, “Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet Oncol, vol. 17, no. 1, p. 89, 2016.
, “Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.”, Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.
, “Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.”, Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S42-7, 2014.
, “Incorporation of pazopanib in maintenance therapy of ovarian cancer.”, J Clin Oncol, vol. 32, no. 30, p. 3382, 2014.
, “Optimal treatment of early-stage ovarian cancer.”, Ann Oncol, vol. 25, no. 6, pp. 1165-71, 2014.
, , “Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.”, Ann Oncol, vol. 24, no. 12, pp. 3028-34, 2013.
, “First-line therapy in ovarian cancer trials.”, Int J Gynecol Cancer, vol. 21, no. 4, pp. 756-62, 2011.
, “Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.”, Int J Gynecol Cancer, vol. 20, no. 7, pp. 1290-8, 2010.
, “Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.”, Ann Oncol, vol. 21, no. 4, pp. 759-65, 2010.
, “Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer”, Int J Gynecol Cancer, vol. 20, pp. 945-52, 2010.
, “Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.”, J Clin Oncol, vol. 27, no. 9, pp. 1419-25, 2009.
, “Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Por”, J Clin Oncol, vol. 23, pp. 4137-45, 2005.
, “International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer”, J Natl Cancer Inst, vol. 95, pp. 125-32, 2003.
, “International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.”, J Natl Cancer Inst, vol. 95, no. 2, pp. 125-32, 2003.
, “International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma”, J Natl Cancer Inst, vol. 95, pp. 105-12, 2003.
, “Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial”, Lancet, vol. 361, pp. 2099-106, 2003.
, “Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.”, Lancet, vol. 361, no. 9375, pp. 2099-106, 2003.
, “Medical therapy of advanced malignant epithelial tumours of the ovary”, Forum (Genova), vol. 10, pp. 323-32, 2000.
, ,
“European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion”, J Clin Oncol, vol. 12, pp. 2654-66, 1994.
, “European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.”, J Clin Oncol, vol. 12, no. 12, pp. 2654-66, 1994.
,